Showing 5451-5460 of 7030 results for "".
- Simple Laser Treatments May Help Prevent Nonmelanoma Skin Cancerhttps://practicaldermatology.com/news/simple-laser-treatments-may-help-prevent-nonmelanoma-skin-cancer/2461508/Nonablative fractional lasers treatments may help prevent basal cell carcinoma and squamous cell carcinoma, a new study suggests. Nonablative fractional lasers (NAFL) are currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for pre
- Investigational Topical Peptide May Help Tame Eczemahttps://practicaldermatology.com/news/investigational-topical-peptide-may-help-tame-eczema/2461503/A new investigational topical peptide may can block inflammatory signaling in a preclinical model of atopic dermatitis – eczema, researchers at Vanderbilt University Medical Center (VUMC) report. Treatment for severe cases of eczema includes immunosuppressive drugs
- Algae May Enhance Skin Regeneration and Wound Healing: Studyhttps://practicaldermatology.com/news/algae-may-enhance-skin-regeneration-and-wound-healing-study/2461496/Euglena gracilis may enhance skin regeneration to speed wound healing, according to new research. Investigators developed a system based on microvesicles that bud from the cell surface of Euglena gracilis, a freshwater single-celled green algae, and conta
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D arr
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Acelyrin Inc. to Accelerate Development of Izokibep in HShttps://practicaldermatology.com/news/acelyrin-incs-to-accelerate-development-of-izokibep-in-hs/2461484/Acelyrin Inc’s Izokibep achieved higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label Part A of a Phase 2b/3 trial. Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor
- Apyx Medical Launches #ThisIsMe Campaign for Renuvionhttps://practicaldermatology.com/news/apyx-medical-launches-thisisme-campaign-for-renuvion/2461478/Apyx Medical Corporation is rolling out its first-ever direct-to-consumer brand campaign for Renuvion, a proprietary helium plasma and radiofrequency technology. The #ThisIsMe campaign is aimed at U.S. consumers who are interested in a minimally invas
- Soligenix Initiates Phase 2 Trial of SGX302 for Mild to Moderate Psoriasishttps://practicaldermatology.com/news/soligenix-initiates-phase-2-trial-of-sgx302-for-mild-to-moderate-psoriasis/2461471/Patient enrollment has been opened for Soligenix, Inc.'s Phase 2a study evaluating SGX302 (synthetic hypericin) for the treatment of mild to moderate psoriasis. "We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psor
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and